Arrowhead Pharmaceuticals Inc. has announced the approval of inducement grants for 38 new employees as part of their compensation plan. Approved by the company's Board of Directors on July 22, 2025, these grants allow employees to receive up to 52,680 restricted stock units collectively. These grants are issued under NASDAQ Listing Rule 5635(c)(4) and are separate from the company's stockholder-approved equity incentive plans. The granted stock units will vest annually over a period of four years.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250724305406) on July 24, 2025, and is solely responsible for the information contained therein.